Gilead Sciences (GILD) : Columbus Circle Investors reduced its stake in Gilead Sciences by 0.9% during the most recent quarter end. The investment management company now holds a total of 3,197,838 shares of Gilead Sciences which is valued at $270,792,922 after selling 28,893 shares in Gilead Sciences , the firm said in a disclosure report filed with the SEC on May 3, 2016.Gilead Sciences makes up approximately 2.46% of Columbus Circle Investors’s portfolio.
Other Hedge Funds, Including , Municipal Employees’ Retirement System Of Michigan reduced its stake in GILD by selling 2,340 shares or 4.4% in the most recent quarter. The Hedge Fund company now holds 50,880 shares of GILD which is valued at $4,308,518. Gilead Sciences makes up approx 0.29% of Municipal Employees’ Retirement System Of Michigan’s portfolio.Tokio Marine Asset Management Co Ltd reduced its stake in GILD by selling 517 shares or 1.17% in the most recent quarter. The Hedge Fund company now holds 43,672 shares of GILD which is valued at $3,698,145. Gilead Sciences makes up approx 0.37% of Tokio Marine Asset Management Co Ltd’s portfolio.First Midwest Bank Trust Division boosted its stake in GILD in the latest quarter, The investment management firm added 20,674 additional shares and now holds a total of 88,229 shares of Gilead Sciences which is valued at $7,782,680. Gilead Sciences makes up approx 1.02% of First Midwest Bank Trust Division’s portfolio.Quadrant Capital Management boosted its stake in GILD in the latest quarter, The investment management firm added 1,379 additional shares and now holds a total of 29,825 shares of Gilead Sciences which is valued at $2,630,863. Gilead Sciences makes up approx 2.20% of Quadrant Capital Management’s portfolio.Dorchester Wealth Management Co boosted its stake in GILD in the latest quarter, The investment management firm added 22,460 additional shares and now holds a total of 34,535 shares of Gilead Sciences which is valued at $3,520,153. Gilead Sciences makes up approx 1.29% of Dorchester Wealth Management Co’s portfolio.
Gilead Sciences opened for trading at $86.41 and hit $86.48 on the upside on Tuesday, eventually ending the session at $86.18, with a gain of 0.60% or 0.51 points. The heightened volatility saw the trading volume jump to 68,40,044 shares. Company has a market cap of $114,776 M.
On the company’s financial health, Gilead Sciences reported $3.03 EPS for the quarter, missing the analyst consensus estimate by $ -0.10 based on the information available during the earnings call on Apr 28, 2016. Analyst had a consensus of $3.13. The company had revenue of $7794.00 million for the quarter, compared to analysts expectations of $8065.42 million. The company’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.94 EPS.
Many Wall Street Analysts have commented on Gilead Sciences. Gilead Sciences was Downgraded by Maxim Group to ” Hold” on Apr 29, 2016. Shares were Reiterated by UBS on Apr 29, 2016 to “Buy” and Lowered the Price Target to $ 118 from a previous price target of $130 .Shares were Reiterated by Leerink Partners on Mar 16, 2016 to “Outperform” and Lowered the Price Target to $ 127 from a previous price target of $130 .
Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.